{"id":"W4389516746","doi":"10.1016/j.annonc.2023.09.3104","title":"Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; McGill University; Jewish General Hospital","funders":"Foundation Medicine; EMD Serono; Eisai; Sanofi; Seagen; Pfizer; Genentech; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Fulvestrant; Medicine; Tolerability; Metastatic breast cancer; Internal medicine; Palbociclib; Oncology; Aromatase inhibitor; Breast cancer; Estrogen receptor; Pharmacology; Cancer; Adverse effect; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001177722,0.0002298095,0.001065759,0.00009516345,0.0001518861,0.000008863858,0.0001751842,0.00008919129,0.0001446063],"category_scores_gemma":[0.0004883513,0.0001387548,0.0002021521,0.0003661223,0.0004730099,0.0001489079,0.00002921986,0.0001688964,0.000005838976],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005622103,"about_ca_system_score_gemma":0.0006287525,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007267153,"about_ca_topic_score_gemma":0.0006478629,"domain_scores_codex":[0.9979792,0.0002945456,0.0006539547,0.000388214,0.0002983543,0.0003857502],"domain_scores_gemma":[0.995493,0.003034315,0.0004770991,0.000405685,0.0004486624,0.0001412649],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8435625,0.0006603628,0.000001447607,0.00002086897,0.001199888,0.00007924461,0.001763781,0.0003920669,0.0003866178,0.0001660414,0.0009357129,0.1508314],"study_design_scores_gemma":[0.9564103,0.0211397,0.0001369625,0.00009576017,0.0008502646,0.00008118761,0.001279626,0.0007820397,0.001284004,0.001286785,0.01648694,0.0001663774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9261352,0.0007519596,0.001079575,0.06452105,0.0008843799,0.003227244,0.002990067,0.0001220677,0.0002884397],"genre_scores_gemma":[0.9900022,0.0004877842,0.003822147,0.001761865,0.001419846,0.001169675,0.0009229024,0.00006312066,0.000350437],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.150665,"threshold_uncertainty_score":0.5658256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1329716577952149,"score_gpt":0.4527071083608898,"score_spread":0.3197354505656749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}